alexa Development Of A Vaccine Candidate Against Crimean-congo Haemorrhagic Fever (CCHF) Virus
ISSN: 1948-5964

Journal of Antivirals & Antiretrovirals
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th World Congress on Virology
October 06-08, 2014 Hilton San Antonio Airport, TX, USA

Dowall SD, Buttigieg KR, Findlay-Wilson S, Miloszewska A, Rayner E, Graham VA, Carroll MW and Hewson R
ScientificTracks Abstracts: J Antivir Antiretrovir
DOI: 10.4172/1948-5964.S1.020
Crimean-Congo Haemorrhagic Fever (CCHF) is a severe tick-borne disease, endemic in many countries in Africa, the Middle East, Eastern Europe and Asia. Between 15-70% of reported cases are fatal. There is no approved vaccine available and preclinical protection in vivo by an experimental vaccine has not been demonstrated previously. PHE scientists have developed a recombinant candidate vaccine expressing the CCHF virus glycoproteins in an attenuated poxvirus vector, Modified Vaccinia virus Ankara. Cellular and humoral immunogenicity was confirmed in two mouse strains, including type I interferon receptor knockout mice, which are susceptible to CCHF disease. This vaccine protected all recipient animals from lethal disease in a challenge model adapted to represent infection via a tick bite. Histopathology and viral load analysis of protected animals confirmed that they had been exposed to challenge virus, even though they did not exhibit clinical signs. This is the first demonstration of efficacy of a CCHF vaccine.
Dowall SD joined the research division of Public Health England (PHE) starting in the HIV vaccine research group that used the SIV model in rhesus macaques. During 2004, he transferred these skills to a group set up to establish the non-human primate model of TB. With a keen interest in virology and in vivo modelling, Stuart moved to the Virology and Pathogenesis research group in 2009. Within this group he has established immunological assays with viruses, and has undertaken work at Containment Level 4, primarily with Ebola and Crimean-Congo Haemorrhagic Fever (CCHF) viruses. He is Project Team Leader for multiple projects within the group studying arboviruses, haemorrhagic fever viruses and vaccines/therapeutic interventions against these pathogens.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version